4 research outputs found
Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis
© 2015 The Authors. Published by Springer Nature. This is an open access article available under a Creative Commons licence.
The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1038/srep12955Faecal microbiota transplantation (FMT) is effective in the treatment of Clostridium difficile infection, where efficacy correlates with changes in microbiota diversity and composition. The effects of FMT on recipient microbiota in inflammatory bowel diseases (IBD) remain unclear. We assessed the effects of FMT on microbiota composition and function, mucosal immune response, and clinical outcome in patients with chronic pouchitis. Eight patients with chronic pouchitis (current PDAI ‰7) were treated with FMT via nasogastric administration. Clinical activity was assessed before and four weeks following FMT. Faecal coliform antibiotic sensitivities were analysed, and changes in pouch faecal and mucosal microbiota assessed by 16S rRNA gene pyrosequencing and 1 H NMR spectroscopy. Lamina propria dendritic cell phenotype and cytokine profiles were assessed by flow cytometric analysis and multiplex assay. Following FMT, there were variable shifts in faecal and mucosal microbiota composition and, in some patients, changes in proportional abundance of species suggestive of a 'healthier' pouch microbiota. However, there were no significant FMT-induced metabolic or immunological changes, or beneficial clinical response. Given the lack of clinical response following FMT via a single nasogastric administration our results suggest that FMT/bacteriotherapy for pouchitis patients requires further optimisation.Published versio
Physical function and quality of life in patients with chronic graft-versus-host-disease: A summary of preclinical and clinical studies and a call for exercise intervention trials in patients
Allogeneic Hematopoietic Stem Cell Transplant, to reconstitute hematopoietic and immune status
of patients undergoing myeloablative therapy for hematologic disorders, has been of great benefit
in minimizing or eradicating disease and extending survival. Patients who undergo allogeneic
hematopoietic stem cell transplant (allo-HSCT) are subject to many comorbidities among which
the most significant, affecting quality of life (QoL) and survival, are acute (aGVHD) and chronic
Graft Versus Host Disease (cGVHD), resulting from donor lymphocytes reacting to and damaging
host tissues. Physical activity and exercise have clearly been shown, in both children and adults, to
enhance fitness, improve symptomatology and QoL, reduce disease progression and extend
survival for many diseases including malignancies. In some cases, vigorous exercise has been
shown to be equal to or more effective than pharmacologic therapy. This review addresses how
cGVHD affects patients’ physical function and physical domain of QoL, and the potential benefits
of exercise interventions along with recommendations for relevant research and evaluation targeted at incorporating this strategy as soon as possible after allo-HSCT and ideally, as soon as
possible upon diagnosis of the condition leading to allo-HSCT.Sin financiación3.874 JCR (2016) Q2, 20/70 Hematology, 48/151 Immunology, 71/217 Oncology, 7/25 Transplantation1.986 SJR (2016) Q1, 18/135 Hematology, 5/42 TransplantationNo data IDR 2016UE